Active ingredient: tilorone dihydrochloride 125 mg.
Inactive ingredients: magnesium hydroxycarbonate, povidone K30 and calcium stearate
1 tablet per day during the first 2 days, then 1 tablet once every 2 days.
To be administered orally after meal.
Maximum dose for influenza and ARVI treatment course is 750 mg (6 tablets).
Maximum dose for herpes and other viral infections treatment course is 1.25–2.5 mg (10–20 tablets).
Allergic response, dyspepsia and short-term chills.
No cases of overdose were recorded.
The drug can be co-administered with antibiotics and medicines treating viral and bacterial diseases. No significant drug interactions were recorded.
Store in a dark place at a temperature not higher than 25°C (77°F). Keep out of the reach of children.
Shelf life is 2 years.
Lavomax is an immunomodulating and antiviral drug intended for treatment and prevention of respiratory and other viral diseases.
Tilorone, its active ingredient, stimulates the production of interferons (proteins essential for anti-viral defence) and enhances the immunity during influenza and ARVI. The synthesis method and antiviral properties of tilorone were first patented in 1968 in the USA. In USSR the production and use of this drug started in 1975.
Research demonstrated that Lavomax is effective in treating viral infections, including influenza and other acute respiratory viral infections, hepatitis and herpes, cytomegalovirus and neurotropic viruses. The drug inhibits viral translation in the infected cells and prevents the spread of viruses, thus showing a strong antiviral effect.
Lavomax stimulates the production of alpha, beta, and gamma types of interferons in intestinal epithelial cells, hepatocytes, T-cells and neutrophils.
It also contributes to the growth of bone marrow cells and enhances antibody production, stabilizes the level of immunosuppression and regulates the T-Lymphocyte Helper/Suppressor ratio.
As part of complex therapy of:
Hypersensitivity to tilorone and other components of the drug.
Pregnancy and lactation.
Children under 18 years of age.
Sucrase-isomaltase deficiency, fructose intolerance or glucose-galactose malabsorption (the drug contains sucrose).
- Glaz et al (1973) Antiviral Activity and Induction of Interferon-Like Substance by Quinacrine and Acranil https://www.ncbi.nlm.nih.gov/pmc/articles/PMC444452/
- Levine et al (1975) Nuclear bodies produced in astrocytes by tilorone https://www.ncbi.nlm.nih.gov/m/pubmed/163594/
- Kuehne et al (1977) Evaluation of Various Analogues of Tilorone Hydrochloride Against Venezuelan Equine Encephalitis Virus in Mice https://www.ncbi.nlm.nih.gov/pmc/articles/PMC351924/
- Donahoe et al (1977) In vivo function tests of the effect of tilorone and niridazole on cell-mediated immunity in chickens https://www.ncbi.nlm.nih.gov/pubmed/23063
- Kavetskiĭ et al (1977) Tilorone, a synthetic immunostimulator possessing antitumor activity https://www.ncbi.nlm.nih.gov/pubmed/413265
- Cummings et al (1981) Phase II trials of Baker's antifol, bleomycin, CCNU, streptozotocin, tilorone, and 5-fluorodeoxyuridine plus arabinosyl cytosine in metastatic breast cancer https://www.ncbi.nlm.nih.gov/pubmed/6166363
- Y Hiyama, K Kuriyama et al (1991) Dissociation between antiinflammatory action of tilorone and its interferon inducing activity https://www.ncbi.nlm.nih.gov/pubmed/1719782
- Selkova et al (2001) Effect of amyxin--a domestic analog of tilorone--on characteristics of interferon and immune status of man https://www.ncbi.nlm.nih.gov/pubmed/11569258
- Briggs et al (2008) α7 nicotinic acetylcholine receptor agonist properties of tilorone and related tricyclic analogues https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2267268/
- Ratan et al (2010) Small Molecule Activation of Adaptive Gene Expression. Tilorone or Its Analogs Are Novel Potent Activators of Hypoxia Inducible Factor-1 That Provide Prophylaxis against Stroke and Spinal Cord Injury https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921907/
- Schrimpf et al (2012) SAR of α7 nicotinic receptor agonists derived from tilorone: exploration of a novel nicotinic pharmacophore https://www.ncbi.nlm.nih.gov/pubmed/22281189
- Leppäranta et al (2013) Bone morphogenetic protein-inducer tilorone identified by high-throughput screening is antifibrotic in vivo https://www.ncbi.nlm.nih.gov/pubmed/23258233
- Wissing et al (2014) Small-molecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression https://www.ncbi.nlm.nih.gov/pubmed/24841903
- Ekins et al (2018) Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection https://www.ncbi.nlm.nih.gov/pubmed/29133569
- Vartiainen et al (2018) Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice https://www.ncbi.nlm.nih.gov/pubmed/29655797